NCT06923072View on ClinicalTrials.gov

Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

December 14, 2030

Study Completion Date

December 15, 2030

Conditions
Kohlmeier-Degos DiseaseMalignant Atrophic PapulosisDegos DiseasePapulosis, Malignant Atrophic
Interventions
DRUG

Baricitinib

Participants will be instructed to take baricitinib 4mg oral daily for 24 weeks (with or without food)

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH